Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from Precision BioSciences (DTIL).
Precision BioSciences, Inc. recently announced the successful maturity of a $13 million convertible note, part of a strategic deal with Imugene Limited focusing on the cancer therapy azercabtagene zapreleucel. The company gained $9.75 million in cash and an additional $3.25 million in stock from Imugene, underscoring a significant financial milestone and a strengthened partnership in oncology.
For an in-depth examination of DTIL stock, go to TipRanks’ Stock Analysis page.
